Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Routine genomic testing is feasible, but only a subset of patients benefit

Molecular profiles and the future of adjuvant therapy

Delaying metastatic prostate cancer, improving survival with abiraterone

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths

Recent childhood cancer survivors face less chronic disease risk than previous decades

EADO conference highlights

Intralesional T-VEC and combinations for melanoma

Molecular testing for targeted therapies

Brain metastases: Gamma knife and new treatments

Essential regional control of skin cancers

Update in anti-CTLA4 and anti-PD1 treatment in advanced melanoma